৳ 90/unit
Pack: ৳ 900
৳ 90/unit
Pack: ৳ 900
At a glance
Tenofovir Alafenamide is a nucleotide reverse transcriptase inhibitor (NRTI) used for the treatment of chronic hepatitis B virus (HBV) infection. It inhibits HBV replication.
Indications
- Chronic hepatitis B (HBV) infection (compensated liver disease, adults)
Pharmacology
Tenofovir Alafenamide enters hepatocytes via OATP1B1/OATP1B3 and is converted to tenofovir by carboxylesterase 1. Tenofovir diphosphate is incorporated into viral DNA by HBV reverse transcriptase, causing DNA chain termination and inhibiting HBV replication.
Dosage
Adult Dose (Oral):
- 25 mg tablet once daily with food
- Renal impairment (eGFR ≥15 mL/min or ESRD on hemodialysis): No dose adjustment needed; administer after dialysis
- Hepatic impairment (Child-Pugh A): No dose adjustment; decompensated (Child-Pugh B/C): Not recommended
Side effects
Common Side Effects:
- Headache
- Abdominal pain
- Fatigue, cough, nausea
- Back pain
Serious:
- Lactic acidosis/severe hepatomegaly with steatosis
- Renal impairment
- Severe exacerbation of hepatitis B (upon treatment discontinuation)
Use in pregnancy
Use in Pregnancy: Generally safe; animal studies show low or no adverse effects; limited human data; consult your doctor.
Pregnancy Category: B — always consult a doctor before taking during pregnancy.
Precautions & warnings
- Do not use alone in HIV-1 coinfected patients (risk of HIV-1 resistance)
- Severe exacerbation of hepatitis B may occur upon discontinuation; monitor for several months after stopping
- New onset or worsening renal impairment: Monitor serum creatinine, eGFR, urine glucose and protein
- Suspend if lactic acidosis is suspected
Overdose effects
In overdose, provide general supportive measures and monitor vital signs; tenofovir is removed by hemodialysis (extraction coefficient approximately 54%).
Storage conditions
Store below 30°C in the original container, protected from light; keep out of reach of children.